Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

2.300 -0.130 (-5.35%)
Streaming Delayed Price Updated: 11:42 AM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ImmunityBio, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Recap Of Thursday's Biotech Catalysts - End of The Day Summary
 
Via Benzinga
FDA Accepts ImmunityBio's Bladder Cancer Candidate For Review
The U.S. Food and Drug Administration (FDA) accepted for review ImmunityBio’s (NASDAQ: IBRX) Biologics License Application (BLA) for its lead asset N-803 in the treatment of patients with... 
Via Benzinga
ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ
From ImmunityBio
Via Business Wire
7 Best Pharmaceutical Stocks to Buy Now
These investments represent the best pharmaceutical stocks. Each offers incredible upside potential in the post-pandemic world. 
Via InvestorPlace
ImmunityBio Expects To Submit US Application For VesAnktiva In Bladder Cancer This Month
ImmunityBio Inc (NASDAQ: IBRX)  
Via Benzinga
ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Submits Biologics License Application for N-803 Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ
From ImmunityBio, Inc.
Via Business Wire
7 Cheap Biotech Stocks to Buy Now
These biotech stocks can be speculative, but have the potential to blow up in the next couple of years for good gains. 
Via InvestorPlace
ImmunityBio To Present Data From Multiple Clinical Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer
From ImmunityBio, Inc.
Via Business Wire
Global Antibiotic Resistance Market to Hit US$16.5 Billion By 2030
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Resistance to antibiotics is a growing concern. About 750,000 people die each year worldwide from... 
Via FinancialNewsMedia
99 Biggest Movers From Yesterday
Gainers Armstrong Flooring, Inc. (NYSE: AFI) shares jumped 237% to settle at $0.49 on Wednesday after a 13D filing showed Esopus Creek Advisors LLC disclosed a 5.1% active stake in the company. 
Via Benzinga
ImmunityBio Provides Updated Status of Biologics License Application (BLA) for VesAnktiva Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ
From ImmunityBio, Inc.
Via Business Wire
Bonds Are Screaming “Recession.” That’s Great News For One Top Sector.
The 10-2 year treasury yield spread is close to zero. Here's what you should do about this warning sign of a coming recession. 
Via InvestorPlace
ImmunityBio's Ankitva Shows 100% Survival At Two Years In Bladder Cancer Setting
ImmunityBio Inc (NASDAQ: IBRX) announced data from its bladder cancer trial (QUILT-3.032) Phase 2/3 study of intravesical BCG plus Anktiva (N-803). The data showed... 
Via Benzinga
Development of Novel Innovative Diagnostic tests Generating Huge Revenue Opportunity for Global Blood Testing Market
Palm Beach, FL – February 16, 2022 – FinancialNewsMedia.com News Commentary – The global blood testing market has grown during the pandemic and is expected to continue to rise in the coming years.... 
Via FinancialNewsMedia
ImmunityBio Completes Acquisition of Athenex’s Interest in Dunkirk, New York Advanced Biotech Manufacturing Facility
From ImmunityBio, Inc.
Via Business Wire
The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage... 
Via Benzinga
ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New ‘Magnitude of Benefit’ in Patients with BCG Unresponsive Bladder Cancer
From ImmunityBio, Inc.
Via Business Wire
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
16 Stocks Moving in Tuesday's Pre-Market Session
Gainers ObsEva SA (NASDAQ: OBSV) rose 22.2% to $1.87 in pre-market trading after the company announced a corporate update, including an increase in share capital on... 
Via Benzinga
ImmunityBio Announces Promising Clinical Study Results for ‘Kick and Kill’ HIV Cure Strategy to Reduce HIV Viral Load with Anktiva (N-803) Therapy
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio's Shares Jump On Encouraging Data From Pancreatic Cancer Immunotherapy Trial
ImmunityBio Inc (NASDAQ: IBRX) has revealed early results from its Phase 2 metastatic pancreatic cancer trial (QUILT 88), showing that patients' overall... 
Via Benzinga
The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH)... 
Via Benzinga
ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Survival
From ImmunityBio, Inc.
Via Business Wire
The Week Ahead In Biotech (Jan 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week
Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Swiss... 
Via Benzinga
ImmunityBio Expands Manufacturing Capacity with State-of-the-Art Manufacturing Plant in New York for Global Pandemic Response and Preparedness
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Awarded Seminal Patent on Natural Killer Cells
From ImmunityBio, Inc.
Via Business Wire
61 Biggest Movers From Yesterday
Gainers Genprex, Inc. (NASDAQ: GNPX) shares surged 167.2% to settle at $3.50 on Monday. The FDA granted Fast Track Designation for Genprex’s lead drug candidate, Reqorsa... 
Via Benzinga
Amyris, ImmunityBio Shares Trading Higher On COVID-19 Vaccine Joint Venture
Amyris Inc (NASDAQ: AMRS) and ImmunityBio (NASDAQ: IBRX) have completed their previously announced joint venture agreement to accelerate the... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.